Osborne Clarke advises MVM Partners on €32 million Series A investment in Avanzanite Bioscience

"Osborne Clarke advised MVM Partners on a €32 million Series A investment in Avanzanite Bioscience. The funding will accelerate Avanzanite’s pan‑European expansion, support current and future rare disease product launches, enable strategic alliances and acquisitions, and help realise its 2032 vision for a pan‑European rare disease platform."

Osborne Clarke advised MVM Partners on its EUR 32 million Series A investment in Avanzanite Bioscience. The transaction comprises a EUR 32 million Series A financing in Avanzanite Bioscience, a commercial-stage European specialty pharmaceutical company focused on rare diseases. The strategic funding is intended to accelerate the expansion of Avanzanite’s pan‑European infrastructure and to support both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and to acquire assets to broaden its portfolio, advancing the company toward its 2032 vision of a pan‑European platform with more than ten rare disease alliances and establishing a new European standard for orphan medicine commercialisation and patient access. Osborne Clarke represented MVM Partners with a team composed by: Amsterdam Partner Herke van Hulst, Associate Angela Saldanha, and Amsterdam Partner Jim Margry. The team forms part of Osborne Clarke’s international venture capital and life sciences practice.

Osborne Clarke advises MVM Partners on €32 million Series A investment in Avanzanite Bioscience

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads